BR0315688A - Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas - Google Patents
Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicasInfo
- Publication number
- BR0315688A BR0315688A BR0315688-5A BR0315688A BR0315688A BR 0315688 A BR0315688 A BR 0315688A BR 0315688 A BR0315688 A BR 0315688A BR 0315688 A BR0315688 A BR 0315688A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- conditions
- pharmaceutical compositions
- diseases
- prevention
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"COMPOSTOS, COMPOSIçõES FARMACêUTICAS E SEUS USOS NO TRATAMENTO OU PREVENçãO DE DOENçAS OU CONDIçõES DE PROLIFERAçãO CELULAR E METABóLICAS". São fornecidos aqui, compostos, composições farmacêuticas e processos que são úteis no tratamento ou prevenção de doenças ou condições de proliferação celular e metabólicas. Especificamente, a invenção provê compostos que modulam a atividade das proteínas envolvidas no metabolismo do lipídeo e proliferação celular.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42860002P | 2002-11-22 | 2002-11-22 | |
PCT/US2003/037574 WO2004047755A2 (en) | 2002-11-22 | 2003-11-21 | Fused bicyclic nitrogen-containing heterocycles |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0315688A true BR0315688A (pt) | 2005-09-06 |
Family
ID=32393428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0315688-5A BR0315688A (pt) | 2002-11-22 | 2003-11-21 | Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas |
Country Status (15)
Country | Link |
---|---|
US (2) | US7244727B2 (pt) |
EP (1) | EP1562956A4 (pt) |
JP (1) | JP3988830B2 (pt) |
KR (1) | KR100772297B1 (pt) |
CN (1) | CN1753897A (pt) |
AU (1) | AU2003293006A1 (pt) |
BR (1) | BR0315688A (pt) |
CA (1) | CA2514473C (pt) |
IL (1) | IL168497A0 (pt) |
MX (1) | MXPA05005425A (pt) |
NO (1) | NO20052923L (pt) |
NZ (1) | NZ539952A (pt) |
RU (1) | RU2342388C2 (pt) |
WO (1) | WO2004047755A2 (pt) |
ZA (1) | ZA200503823B (pt) |
Families Citing this family (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7879840B2 (en) | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US7718644B2 (en) | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
AU2003293006A1 (en) * | 2002-11-22 | 2004-06-18 | Japan Tobacco Inc. | Fused bicyclic nitrogen-containing heterocycles |
WO2005013907A2 (en) | 2003-08-07 | 2005-02-17 | Japan Tobacco Inc. | Pyrrolo[1,2-b]pyridazine derivatives |
US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
CA2554455A1 (en) * | 2004-01-30 | 2005-08-11 | Japan Tobacco Inc. | Anorectic |
BRPI0516483A (pt) * | 2004-10-15 | 2008-09-02 | Bayer Pharmaceuticals Corp | preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade |
CA2584507C (en) * | 2004-10-20 | 2016-04-26 | Resverlogix Corp. | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases |
JP2008523133A (ja) | 2004-12-14 | 2008-07-03 | アストラゼネカ アクチボラグ | Dgat阻害剤としてのオキサジアゾール誘導体 |
KR100883694B1 (ko) | 2005-02-07 | 2009-02-12 | 에프. 호프만-라 로슈 아게 | 디아실글리세롤 아실트랜스퍼라제 억제제 |
US20090264650A1 (en) * | 2005-03-31 | 2009-10-22 | Nobuo Cho | Prophylactic/Therapeutic Agent for Diabetes |
BRPI0608906A2 (pt) | 2005-05-10 | 2010-02-17 | Hoffmann La Roche | composto, processo para a sua manufatura, utilização do mesmo, método para o tratamento de obesidade, diabetes do tipo ii ou sìndrome metabólica e composição farmacêutica que compreende o composto |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
US7750015B2 (en) | 2005-05-17 | 2010-07-06 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
WO2006124490A2 (en) * | 2005-05-17 | 2006-11-23 | Schering Corporation | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia |
US20090215779A1 (en) * | 2005-06-11 | 2009-08-27 | Roger John Butlin | Oxadiazole derivatives as dgat inhibitors |
GB0513702D0 (en) | 2005-07-04 | 2005-08-10 | Sterix Ltd | Compound |
US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
JP5076091B2 (ja) | 2005-11-28 | 2012-11-21 | マドリガル・ファーマシューティカルズ・インコーポレーテッド | ジアシルグリセロールアシルトランスフェラーゼ(dgat)のインヒビター |
JPWO2007063839A1 (ja) * | 2005-11-30 | 2009-05-07 | 塩野義製薬株式会社 | シクロヘキサン誘導体 |
JP2009520786A (ja) * | 2005-12-22 | 2009-05-28 | アストラゼネカ アクチボラグ | Dgat阻害剤として使用するためのピリミド−[4,5−b]−オキサジン |
KR20080091814A (ko) * | 2006-01-20 | 2008-10-14 | 쉐링 코포레이션 | 지질혈증장애의 치료를 위한 니코틴산 수용체 효능제로서의헤테로사이클 |
EP2006271A4 (en) * | 2006-03-30 | 2011-08-10 | Asahi Kasei Pharma Corp | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF |
UA97474C2 (ru) * | 2006-03-31 | 2012-02-27 | Новартис Аг | Соединения для лечения нарушений, связанных с активностью dgat1 |
US8084478B2 (en) | 2006-05-30 | 2011-12-27 | Asstrazeneca Ab | Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase |
US8003676B2 (en) | 2006-05-30 | 2011-08-23 | Astrazeneca Ab | 1,3,4-oxadiazole derivatives as DGAT1 inhibitors |
WO2007141517A1 (en) * | 2006-06-08 | 2007-12-13 | Astrazeneca Ab | Benzimidazoles and their use for the treatemnt of diabetes |
GB0611506D0 (en) * | 2006-06-10 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
PL2065388T3 (pl) | 2006-09-19 | 2012-02-29 | Daiichi Sankyo Co Ltd | Pochodna pirazolopirymidynowa |
RU2474576C2 (ru) * | 2006-11-29 | 2013-02-10 | Эбботт Лэборетриз | Ингибиторы фермента диацилглицерин о-ацилтрансфераза типа 1 |
AU2007333234A1 (en) * | 2006-12-11 | 2008-06-19 | Novartis Ag | Method of preventing or treating myocardial ischemia |
WO2008090198A1 (en) * | 2007-01-25 | 2008-07-31 | Janssen Pharmaceutica Nv | Use of mtp inhibitors for increasing levels of satiety hormones |
WO2008092231A1 (en) | 2007-02-01 | 2008-08-07 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular diseases |
EP2120911A1 (en) * | 2007-02-15 | 2009-11-25 | Prosidion Limited | Amide and urea derivatives for the treatment of metabolic diseases |
AU2008254270B2 (en) | 2007-05-16 | 2013-06-06 | Merck Sharp & Dohme Corp. | Spiroindalones |
US8058299B2 (en) * | 2007-05-22 | 2011-11-15 | Via Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
US20090099201A1 (en) * | 2007-05-22 | 2009-04-16 | David Robert Bolin | Diacylglycerol Acyltransferase Inhibitors |
US8115011B2 (en) * | 2007-05-22 | 2012-02-14 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
US8153644B2 (en) * | 2007-05-22 | 2012-04-10 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
PE20090362A1 (es) | 2007-06-08 | 2009-04-04 | Janssen Pharmaceutica Nv | Derivados de piperidina/piperazina como moduladores de dgat |
JO2972B1 (en) | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine / piperazine derivatives |
JP5443342B2 (ja) | 2007-06-08 | 2014-03-19 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ピペリジン/ピペラジン誘導体 |
WO2008148851A1 (en) | 2007-06-08 | 2008-12-11 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
US20090036425A1 (en) * | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
WO2009038974A1 (en) | 2007-09-20 | 2009-03-26 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
AR066169A1 (es) | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
CN101932562B (zh) | 2007-12-20 | 2013-06-12 | 阿斯利康(瑞典)有限公司 | 作为dgat1抑制剂190的氨基甲酰基化合物 |
WO2009126624A1 (en) | 2008-04-11 | 2009-10-15 | Bristol-Myers Squibb Company | Triazolo compounds useful as dgat1 inhibitors |
US8394823B2 (en) | 2008-04-11 | 2013-03-12 | Bristol-Myers Squibb Company | Triazolopyridine compounds useful as DGAT1 inhibitors |
WO2009147170A2 (en) | 2008-06-05 | 2009-12-10 | Janssen Pharmaceutica Nv | Drug combinations comprising a dgat inhibitor and a ppar-agonist |
AU2009262252B2 (en) | 2008-06-26 | 2013-05-02 | Resverlogix Corp. | Methods of preparing quinazolinone derivatives |
US8211884B2 (en) * | 2008-08-06 | 2012-07-03 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
EP3025727A1 (en) * | 2008-10-02 | 2016-06-01 | The J. David Gladstone Institutes | Methods of treating liver disease |
US8324385B2 (en) * | 2008-10-30 | 2012-12-04 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
CN102239165A (zh) * | 2008-12-03 | 2011-11-09 | 维尔制药公司 | 二酰甘油酰基转移酶抑制剂 |
WO2010077861A1 (en) * | 2008-12-17 | 2010-07-08 | Via Pharmaceuticals, Inc | Inhibitors of diacylglycerol aclytransferase |
ES2463097T3 (es) | 2009-01-08 | 2014-05-27 | Resverlogix Corp. | Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares |
TW201038580A (en) | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
WO2010089685A1 (en) | 2009-02-03 | 2010-08-12 | Pfizer Inc. | 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives |
CA2749893A1 (en) | 2009-02-04 | 2010-08-12 | Pfizer Inc. | 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives |
ES2576056T3 (es) | 2009-02-25 | 2016-07-05 | Daiichi Sankyo Company, Limited | Derivados de pirazolopirimidina tricíclica |
JP5795304B2 (ja) | 2009-03-18 | 2015-10-14 | レスバーロジックス コーポレイション | 新規抗炎症剤 |
US20120022057A1 (en) * | 2009-03-18 | 2012-01-26 | Schering Corporation | Bicyclic compounds as inhibitors of diacyglycerol acyltransferase |
EP2408774B1 (en) | 2009-03-20 | 2014-11-26 | Metabasis Therapeutics, Inc. | Inhibitors of diacylglycerol o-acyltransferase 1(dgat-1) and uses thereof |
CA2756786A1 (en) | 2009-03-27 | 2010-09-30 | Bristol-Myers Squibb Company | Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors |
KR102215167B1 (ko) | 2009-04-22 | 2021-02-16 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
TW201103895A (en) | 2009-06-19 | 2011-02-01 | Astrazeneca Ab | Chemical compounds |
WO2011014520A2 (en) | 2009-07-29 | 2011-02-03 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
WO2011031628A1 (en) | 2009-09-14 | 2011-03-17 | Schering Corporation | Inhibitors of diacylglycerol acyltransferase |
CA2774573A1 (en) | 2009-10-09 | 2011-04-14 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
US8394858B2 (en) | 2009-12-03 | 2013-03-12 | Novartis Ag | Cyclohexane derivatives and uses thereof |
US9061012B2 (en) | 2010-03-30 | 2015-06-23 | Novartis Ag | Uses of DGAT1 inhibitors |
US8697739B2 (en) | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
TW201213333A (en) | 2010-08-23 | 2012-04-01 | Daiichi Sankyo Co Ltd | Crystal forms of tricyclic pyrazolopyrimidine derivative |
EP2610259A4 (en) | 2010-08-23 | 2014-01-08 | Daiichi Sankyo Co Ltd | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVE IN FREE CRYSTALLINE FORM |
KR20130013199A (ko) | 2011-07-27 | 2013-02-06 | 한미약품 주식회사 | 신규 피리미딘 유도체 및 이를 활성성분으로 포함하는 약학 조성물 |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
PT2773354T (pt) | 2011-11-01 | 2019-07-17 | Resverlogix Corp | Formulações orais de libertação imediata para quinazolinonas substituídas |
EP2780015B1 (en) | 2011-11-18 | 2017-01-04 | Heptares Therapeutics Limited | Muscarinic m1 receptor agonists |
FR2986232B1 (fr) * | 2012-01-26 | 2014-02-14 | Sanofi Sa | Derives heterocycliques bicycliques, leur preparation et leur application en therapeutique |
KR20130117678A (ko) * | 2012-04-17 | 2013-10-28 | 한미약품 주식회사 | 비시클릭 헤테로아릴 유도체 및 이를 포함하는 약학 조성물 |
WO2014039411A1 (en) | 2012-09-05 | 2014-03-13 | Bristol-Myers Squibb Company | Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists |
US9499482B2 (en) | 2012-09-05 | 2016-11-22 | Bristol-Myers Squibb Company | Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists |
WO2014052619A1 (en) | 2012-09-27 | 2014-04-03 | Irm Llc | Piperidine derivatives and compositions as modulators of gpr119 activity |
WO2014054053A1 (en) | 2012-10-03 | 2014-04-10 | Advinus Therapeutics Limited | Spirocyclic compounds, compositions and medicinal applications thereof |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
WO2014081995A1 (en) * | 2012-11-23 | 2014-05-30 | Glaxosmithkline Llc | Novel compounds as diacylglycerol acyltransferase inhibitors |
WO2014096965A2 (en) | 2012-12-21 | 2014-06-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
US9227985B2 (en) | 2013-03-15 | 2016-01-05 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
US9290514B2 (en) | 2013-07-08 | 2016-03-22 | Incyte Holdings Corporation | Tricyclic heterocycles as BET protein inhibitors |
WO2015066697A1 (en) * | 2013-11-04 | 2015-05-07 | Forum Pharmaceuticals Inc. | Fused morpholinopyrimidines and methods of use thereof |
US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
HUE061770T2 (hu) | 2014-04-23 | 2023-08-28 | Incyte Holdings Corp | 1H-pirrolo[2,3-C]piridin-7(6H)-onok és pirazolo[3,4-C]piridin-7(6H)-onok mint BET fehérjék gátlószerei |
CN105218561B (zh) * | 2014-06-25 | 2018-10-30 | 上海艾力斯医药科技有限公司 | 稠合嘧啶环衍生物、其制备方法及应用 |
US9527864B2 (en) | 2014-09-15 | 2016-12-27 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
UY36391A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
CN104496795B (zh) * | 2014-12-12 | 2016-09-14 | 重庆博腾制药科技股份有限公司 | 一种dgat-1抑制剂中间体的制备方法 |
EP3268007B1 (en) | 2015-03-13 | 2022-11-09 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
AR106520A1 (es) | 2015-10-29 | 2018-01-24 | Incyte Corp | Forma sólida amorfa de un inhibidor de proteína bet |
US11136333B2 (en) | 2016-05-23 | 2021-10-05 | The Texas A&M University System | Functionalized pyrano[2,3-D]pyrimidin-7-one derivatives and methods for their preparation and use |
EP3472157B1 (en) | 2016-06-20 | 2023-04-12 | Incyte Corporation | Crystalline solid forms of a bet inhibitor |
US11351164B2 (en) * | 2016-08-26 | 2022-06-07 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
CN108164548B (zh) * | 2016-12-07 | 2020-09-08 | 四川大学 | 嘧啶并吗啉衍生物及其制备方法和用途 |
WO2019168866A1 (en) * | 2018-02-28 | 2019-09-06 | Dart Neuroscience, Llc | Substituted cyclohexyl compounds as nop inhibitors |
GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
WO2023085931A1 (en) | 2021-11-11 | 2023-05-19 | Koninklijke Nederlandse Akademie Van Wetenschappen | Hepatic organoids |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
JPH05213985A (ja) | 1992-02-10 | 1993-08-24 | Mitsubishi Kasei Corp | ピロールカルボン酸コエンザイムa誘導体 |
US6069143A (en) | 1994-12-20 | 2000-05-30 | Smithkline Beecham Corporation | Fibrinogen receptor antagonists |
JP2001097979A (ja) * | 1999-07-28 | 2001-04-10 | Takeda Chem Ind Ltd | 縮合複素環化合物、その製造法および用途 |
EP1230225A2 (en) * | 1999-11-01 | 2002-08-14 | Eli Lilly And Company | Pharmaceutically active 4-substituted pyrimidine derivatives |
JP2002284741A (ja) | 2001-03-23 | 2002-10-03 | Kitasato Inst:The | ローズリピン誘導体 |
US7491748B2 (en) | 2001-08-09 | 2009-02-17 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
AUPR738301A0 (en) | 2001-08-30 | 2001-09-20 | Starpharma Limited | Chemotherapeutic agents |
KR100460438B1 (ko) | 2001-12-01 | 2004-12-08 | 한국생명공학연구원 | 아실 코에이:디아실글리세롤 아실트랜스퍼라제활성저해제인 신규 폴리아세틸렌계 화합물 및 이의 제조방법 |
JP4164645B2 (ja) | 2002-08-09 | 2008-10-15 | 株式会社大塚製薬工場 | Dgat阻害剤 |
AU2003293006A1 (en) * | 2002-11-22 | 2004-06-18 | Japan Tobacco Inc. | Fused bicyclic nitrogen-containing heterocycles |
-
2003
- 2003-11-21 AU AU2003293006A patent/AU2003293006A1/en not_active Abandoned
- 2003-11-21 MX MXPA05005425A patent/MXPA05005425A/es active IP Right Grant
- 2003-11-21 CN CNA200380109107XA patent/CN1753897A/zh active Pending
- 2003-11-21 BR BR0315688-5A patent/BR0315688A/pt not_active IP Right Cessation
- 2003-11-21 US US10/720,844 patent/US7244727B2/en not_active Expired - Fee Related
- 2003-11-21 WO PCT/US2003/037574 patent/WO2004047755A2/en active Application Filing
- 2003-11-21 JP JP2004555693A patent/JP3988830B2/ja not_active Expired - Fee Related
- 2003-11-21 EP EP03789996A patent/EP1562956A4/en not_active Withdrawn
- 2003-11-21 KR KR1020057009128A patent/KR100772297B1/ko not_active IP Right Cessation
- 2003-11-21 NZ NZ539952A patent/NZ539952A/en unknown
- 2003-11-21 CA CA002514473A patent/CA2514473C/en not_active Expired - Fee Related
- 2003-11-21 RU RU2005119646/04A patent/RU2342388C2/ru active
-
2005
- 2005-05-09 IL IL168497A patent/IL168497A0/en unknown
- 2005-05-12 ZA ZA200503823A patent/ZA200503823B/en unknown
- 2005-06-15 NO NO20052923A patent/NO20052923L/no not_active Application Discontinuation
-
2007
- 2007-05-02 US US11/743,376 patent/US20070244096A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US7244727B2 (en) | 2007-07-17 |
CA2514473A1 (en) | 2004-06-10 |
JP2006509764A (ja) | 2006-03-23 |
NO20052923L (no) | 2005-08-18 |
RU2342388C2 (ru) | 2008-12-27 |
CN1753897A (zh) | 2006-03-29 |
KR20050090986A (ko) | 2005-09-14 |
AU2003293006A1 (en) | 2004-06-18 |
WO2004047755A2 (en) | 2004-06-10 |
EP1562956A4 (en) | 2007-10-10 |
EP1562956A2 (en) | 2005-08-17 |
IL168497A0 (en) | 2009-02-11 |
NO20052923D0 (no) | 2005-06-15 |
MXPA05005425A (es) | 2005-11-23 |
JP3988830B2 (ja) | 2007-10-10 |
WO2004047755A3 (en) | 2004-11-25 |
KR100772297B1 (ko) | 2007-11-02 |
US20040209871A1 (en) | 2004-10-21 |
CA2514473C (en) | 2008-05-27 |
ZA200503823B (en) | 2006-02-22 |
US20070244096A1 (en) | 2007-10-18 |
NZ539952A (en) | 2008-05-30 |
RU2005119646A (ru) | 2006-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0315688A (pt) | Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas | |
NO20050497L (no) | Anvendelse av CETP inhibitorer og eventuelt HMG COA reduserbare inhibitorer og/eller antihypertensiva | |
NO20050795L (no) | Forbindelser, blandinger og fremgangsmater for utnyttelse av samme | |
FI962154A (fi) | Koostumus terapeuttisten tuotteiden in vivo valmistusta varten | |
JO2373B1 (en) | W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors | |
HK1080459A1 (en) | Novel pyrimidineamide derivatives and the use thereof | |
ATE200677T1 (de) | Substituierte tetra- und pentapeptid hemmstoffe der farnesyl protein transferase | |
MY155218A (en) | Small molecules useful in the treatment of inflammatory disease | |
TR200200938T2 (tr) | CCR5 modülatörleri olarak piperidinler | |
BR0309665A (pt) | Tratamento de deficiência de alfa-galactosidase a | |
TR199903331T2 (xx) | Farnesil protein transferas engelleyicileri. | |
TR200102817T2 (tr) | Antiinflamatuar ajanlar olarak faydalı bileşikler | |
MX9703621A (es) | Nuevos derivados aminoacidos con actividad mejorada para la resistencia a drogas multiples. | |
TR200001203T2 (tr) | Yeni birleşik maddeler | |
BR9811956B1 (pt) | naftiridinonas e composição farmacêutica compreendendo as mesmas. | |
DE69905170T2 (de) | Thiazolopyrimidinderivate | |
BR0107643A (pt) | Composições e processos para a terapia e diagnóstico de c ncer de próstata | |
DE69826695D1 (de) | Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen | |
DK0914144T3 (da) | Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi | |
BRPI0411319A (pt) | compostos terapeuticamente ativos e sua utilização | |
IL163951A (en) | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | |
SE9802937D0 (sv) | Novel compounds | |
DE69725882D1 (de) | Adenovirus e4 proteine für induktion von zelltod | |
TR200100637T2 (tr) | Yeni doğal ürün türevleri | |
NO20051159L (no) | Preparater og fremgangsmater for behandling av sykdommer som viser feilsammensetting av aggregering av protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010. |